Patents Assigned to Inhale Therapeutic System, Inc.
-
Patent number: 6503411Abstract: In a composition which has an amorphous, undercooled, glassy phase containing a water-soluble or water-swellable substance in an amorphous form, a sugar, which is capable of existing as a crystalline hydrate, is used as an agent to dehydrate the amorphous phase by crystallisation therefrom, and thereby enhance the glass transition temperature of the residual amorphous phase.Type: GrantFiled: May 22, 2000Date of Patent: January 7, 2003Assignee: Inhale Therapeutic Systems, Inc.Inventors: Felix Franks, Barry John Aldous, Anthony Auffret
-
Patent number: 6479049Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.Type: GrantFiled: February 17, 2000Date of Patent: November 12, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, Shigenobu Kimura, Yu-ichiro Satoh, Linda C. Foster
-
Patent number: 6440337Abstract: The invention provides a method and apparatus for forming particles of a substance, comprising (a) introducing into a particle formation chamber, the temperature and pressure in which are controlled, a first supercritical fluid (SCF) and a solution or suspension of the substance in a vehicle; (b) simultaneously introducing an impinging flow of a second supercritical fluid (SCF), at an angle to, and directed at, the direction of flow of the first supercritical fluid, so as to increase the amount of kinetic energy transferred to the solution or suspension; and (c) using either or both of the first and the second supercritical fluids to disperse the solution or suspension, and to extract the vehicle from it, substantially simultaneously and substantially immediately on introduction of the fluids into the particle chamber.Type: GrantFiled: December 16, 1999Date of Patent: August 27, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Mazen Hanna, Peter York
-
Patent number: 6433040Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.Type: GrantFiled: December 22, 1998Date of Patent: August 13, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov, Jeffry G. Weers, Ernest G. Schutt
-
Patent number: 6426210Abstract: Materials which are not themselves storage-stable at room temperature are made suitable for storage by mixing them with a carrier substance and spray drying the resulting mixture so as to form particles containing both the material and the carrier substance in which the carrier substance is in an amorphous, i.e. glassy or rubbery, state. Formation of such a composition greatly enhances stability. The material stored may be a biological material such as an enzyme, the components of a chemical reaction such as reagents for carrying out an assay, or even viable biological cells.Type: GrantFiled: May 24, 1999Date of Patent: July 30, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Felix Franks, Ross Henry Hatley, Sheila Frances Mathias
-
Patent number: 6413547Abstract: This invention relates to novel, liquid crystal forms of the cyclic peptide cyclosporin and to novel powder formulations of cyclosporin prepared using this novel liquid crystal form of the drug. Methods for preparing and using these formulations are also provided. In particular, the present invention relates to dispersible spray dried particles of cyclosporin suitable for pulmonary delivery.Type: GrantFiled: February 11, 1999Date of Patent: July 2, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: David B. Bennett, Kirsten M. Cabot, Linda C. Foster, David Lechuga-Ballesteros, John S. Patton, Trixie K. Tan
-
Publication number: 20020065399Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).Type: ApplicationFiled: August 7, 2001Publication date: May 30, 2002Applicant: Inhale Therapeutic Systems, Inc.Inventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
-
Patent number: 6365190Abstract: Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics.Type: GrantFiled: March 17, 2000Date of Patent: April 2, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Marc S. Gordon, Andrew Clark, Thomas K. Brewer
-
Patent number: 6358530Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.Type: GrantFiled: September 25, 2000Date of Patent: March 19, 2002Assignee: Inhale Therapeutic Systems, Inc.Inventors: Mohammad Eljamal, John S. Patton, Linda Foster, Robert M. Platz
-
Patent number: 6309623Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.Type: GrantFiled: December 22, 1998Date of Patent: October 30, 2001Assignee: Inhale Therapeutic Systems, Inc.Inventors: Jeffry G. Weers, Ernest G. Schutt, Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov
-
Patent number: 6303582Abstract: A dry powder composition comprises nucleic acid constructs dispersed within with a hydrophilic excipient material, where the powder particles have an average size in the range from 0.5 &mgr;m to 50 &mgr;m. Nucleic acid constructs may comprise bare nucleic acid molecules, viral vectors, or vesicle structures. The hydrophilic excipient material will be selected to stabilize the nucleic acid molecules in the constructs, enhance dispersion of the nucleic acid in dry powder aerosols, and enhance wetting of the nucleic acid constructs as they are delivered to moist target locations within the body.Type: GrantFiled: October 26, 1999Date of Patent: October 16, 2001Assignee: Inhale Therapeutic Systems, Inc.Inventors: Mohammed Eljamal, John S. Patton, Linda Foster, Robert M. Platz
-
Patent number: 6294204Abstract: The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter≦8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surface-active substance (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.Type: GrantFiled: September 25, 1998Date of Patent: September 25, 2001Assignee: Inhale Therapeutic Systems, Inc.Inventors: Georg Rössling, Celal Albayrak, Johannes Tack, Reinhard Schmitz
-
Patent number: 6267155Abstract: Methods, systems and apparatus for the metered transport of fine powders into receptacles. According to one exemplary method, the fine powder is first fluidized. At least a portion of the fluidized fine powder is then captured. The captured fine powder is then transferred to a receptacle, with the transferred powder being sufficiently uncompacted so that it may be dispersed upon removal from the receptacle.Type: GrantFiled: September 3, 1998Date of Patent: July 31, 2001Assignee: Inhale Therapeutic Systems Inc.Inventors: Derrick J. Parks, Michael J. Rocchio, Kyle Naydo, Dennis E. Wightman, Adrian E. Smith
-
Patent number: 6258341Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage from having a moisture barrier, in combination with appropriate labelling instructions.Type: GrantFiled: October 17, 1996Date of Patent: July 10, 2001Assignee: Inhale Therapeutic Systems, Inc.Inventors: Linda C. Foster, Mei-chang Kuo, Sheila R. Billingsley
-
Patent number: 6207135Abstract: The invention relates to gaseous microparticles for ultrasonic diagnosis, whose wall material is built up from block copolymers of polyesters of &agr;-, &bgr;- or &ggr;-hydroxycarboxylic acids with linear or star-shaped polyethylene glycols and optionally liquid crystals or whose wall material is built up from polyesters of &agr;-, &bgr;- or &ggr;-hydroxycarboxylic acids and liquid crystals, media that contain these particles for ultrasonic diagnosis, as well as a process for the production of the media and particles.Type: GrantFiled: March 30, 1999Date of Patent: March 27, 2001Assignee: Inhale Therapeutic Systems, Inc.Inventors: Georg Rössling, Celal Albayrak, Matthias Rothe
-
Patent number: 6165463Abstract: This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.Type: GrantFiled: June 1, 1999Date of Patent: December 26, 2000Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
-
Patent number: 6123936Abstract: According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.Type: GrantFiled: November 22, 1999Date of Patent: September 26, 2000Assignee: Inhale Therapeutics Systems, Inc.Inventors: Robert M. Platz, Shigenobu Kimura, Yu-ichiro Satoh, Linda C. Foster
-
Patent number: 6019968Abstract: This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.Type: GrantFiled: October 16, 1997Date of Patent: February 1, 2000Assignee: Inhale Therapeutic Systems, Inc.Inventors: Robert M. Platz, John S. Patton, Linda C. Foster, Mohammed Eljamal
-
Patent number: 5994314Abstract: A dry powder composition comprises insoluble nucleic acid constructs dispersed within with a hydrophilic excipient material, where the powder particles have an average size in the range from 0.5 .mu.m to 50 .mu.m. Nucleic acid constructs may comprise bare nucleic acid molecules, viral vectors, or vesicle structures. The hydrophilic excipient material will be selected to stabilize the nucleic acid molecules in the constructs, enhance dispersion of the nucleic acid in dry powder aerosols, and enhance wetting of the nucleic acid constructs as they are delivered to moist target locations within the body.Type: GrantFiled: April 14, 1995Date of Patent: November 30, 1999Assignee: Inhale Therapeutic Systems, Inc.Inventors: Mohammed Eljamal, John S. Patton, Linda Foster, Robert M. Platz
-
Patent number: RE37872Abstract: A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.Type: GrantFiled: March 17, 1999Date of Patent: October 8, 2002Assignee: Inhale Therapeutics Systems, Inc.Inventors: Felix Franks, Ross H. M. Hatley